Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial
| Autor: | Boccardo, Francesco, Barichello, Mario, Battaglia, Michele, Carmignani, Giorgio, Comeri, Giancarlo, Ferraris, Valentino, Lilliu, Sergio, Montefiore, Franco, Portoghese, Filippo, Cortellinik, Pietro, Rigatti, Patrizio, Usai, Enzo, Rubagotti, Alessandra, Muzzonigro, G., Di Santo, V., Selvaggi, F. P., Borin, D., Lilliu, S., Usai, E., Dammino, S., Salvia, G., Consoli, C., Motta, M., Comeri, G., Rizzo, M., Pellegrino, A., Fabbri, F., Boccardo, F., Carmignani, G., Paolini, R., Cruciani, G., Santelli, G., Rigatti, P., Malagola, G., Ferrari, P., Montefiore, F., Pinna, A., Piazza, B., Pavone, M., Cortellini, P., Porena, Massimo |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Male
medicine.medical_specialty Bicalutamide medicine.drug_class Urology Antineoplastic Agents Antiandrogen Flutamide Tosyl Compounds chemistry.chemical_compound Prostate cancer Antineoplastic Combined Chemotherapy Protocols Nitriles medicine Clinical endpoint Antiandrogen monotherapy Humans Anilides Survival analysis Aged Aged 80 and over business.industry Goserelin Prostatic Neoplasms Middle Aged Prostate-Specific Antigen medicine.disease Survival Analysis Surgery Prostate-specific antigen Treatment Outcome chemistry Disease Progression business medicine.drug |
| Zdroj: | European urology. 42(5) |
| ISSN: | 0302-2838 |
| Popis: | Objectives: To compare the efficacy of bicalutamide monotherapy to maximal androgen blockade in advanced prostatic cancer. Patients and Methods: Previously untreated patients with histologically proven stage C or D (American Urological Association Staging System) disease were randomly allocated to either bicalutamide (B) or goserelin plus flutamide (G+F). After disease progression, patients treated with B were assigned to castration. The primary endpoint for this trial was overall survival. Prostate cancer-specific survival and progression were included among secondary endpoints. Results: In total 108 patients received B and 112 received G+F. At a median follow-up time of 54 months (range 1–89), 151 patients progressed and 113 died. There was no significant difference in the duration of either progression-free or overall survival. Hazards of progression, death and cancer-specific death, corrected by disease stage, tumor grade and baseline PSA level, showed that patients initially assigned to B had a higher risk of progression but a comparable risk of death and cancer-specific death with the exception of patients with G3 tumors who had an increased risk of death). Conclusions: In patients with well or moderately well differentiated tumors, B monotherapy followed by castration may offer the same survival chance as maximal androgen deprivation. In those patients it thus represents a reasonable choice that can avoid the side effects of androgen deprivation for considerable periods of time. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect